AURA3: Numbness or tingling in hands or feet
Project Patient Voice is intended to be used with a healthcare professional when discussing the potential symptoms related to a cancer and cancer treatment. Do not rely on Project Patient Voice alone to make decisions about medical care. Do not use Project Patient Voice to substitute for advice from your health care professional. Conclusions about patient experiences with symptoms may be limited because not all symptoms may have been captured by the patient-reported questionnaire.
Download symptom data (XLSX, 24KB)
In AURA3 Study, Patients Were Asked: "In the last 7 days, what was the SEVERITY of your NUMBNESS OR TINGLING IN YOUR HANDS OR FEET at its WORST?"
Patients scored the severity of their Numbness or Tingling in Hands or Feet on a 5-point scale (None, Mild, Moderate, Severe, Very Severe)
All Patients Who Completed the Questionnaire Described Their Experience of Numbness & Tingling During the First 24 Weeks on Treatment:
Figure 1 shows the percentage of patients reporting the severity of their Numbness or Tingling in Hands or Feet at each time point. For example, at week 2, 21% of patients taking Tagrisso reported Numbness or Tingling in Hands or Feet (ranging from Mild to Moderate). The range of patients who had any Numbness or Tingling in Hands or Feet during the first 24 weeks of treatment with Tagrisso was between 19% - 36%. Click here for more information on how to read the graphs below.
Figure 1. Patient-Reported Numbness or Tingling in Hands or Feet During the First 24 Weeks on Treatment
All responses from patients' experiences just before and up to week 24 on-treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.
Worst Response Option for Numbness or Tingling in Hands or Feet That Patients Reported During the First 24 Weeks on Treatment
Figure 2. Worst Patient-Reported Numbness or Tingling in Hands or Feet During the First 24 Weeks on Treatment
Patients with at least one on-treatment Numbness or Tingling in Hands or Feet score were included in the analysis. Tagrisso (N=99), Chemotherapy (N=55).
Some Patients Did Not Report Numbness or Tingling in Hands or Feet Before Treatment:
For patients that did not report Numbness or Tingling in Hands or Feet before treatment, Figure 3 shows the percentage of patients reporting the severity of their Numbness or Tingling in Hands or Feet between weeks 1 and 24.
Figure 3. Patient-Reported Numbness or Tingling in Hands or Feet During the First 24 Weeks on Treatment: Patients Without Numbness or Tingling in Hands or Feet Before Treatment
All responses from patients who did not report Numbness or Tingling in Hands or Feet before treatment were included in the analysis. Some patients did not report their symptoms every week, therefore the number of patients may vary between weeks. Furthermore, not all patients remained on the treatment for 24 weeks (e.g., some stop treatment for worsening disease) which is a reason for the change in the number of patients over the course of treatment.
Worst Response Option for Numbness or Tingling in Hands or Feet That Patients Reported During the First 24 Weeks on Treatment, for Patients Who Did Not Have Numbness or Tingling in Hands or Feet Before Treatment:
Figure 4. Worst Patient-Reported Numbness or Tingling in Hands or Feet During the First 24 Weeks on Treatment: Patients Without Numbness or Tingling in Hands or Feet Before Treatment
Patients who had no Numbness or Tingling in Hands or Feet before treatment and at least one on-treatment Numbness or Tingling in Hands or Feet score were included in the analysis. Tagrisso (N=61), Chemotherapy (N=31).